Live Analyst Rating Changes 3274 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Kostas Biliouris
OPCO
Kostas Biliouris
Oppenheimer
Wall Street Analyst
★★★☆☆
#1614
on 13Foresight · ranked by our own returns
47%
Success Rate
+8.5%
Average Return
15 of 32 calls profitable · +0.4% vs benchmark
🔒 3-year track record is Pro. Showing 1-year — upgrade.
📈 Across the calls we could measure, roughly 47% of Kostas Biliouris's ratings turned a profit when each position was held for 1 year — averaging +8.5% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

73 Buy 35 Hold 0 Sell
Kostas's Stock Coverage 28 ratings · 2026-06-27
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
ALNY
Alnylam Pharma
 Jun 25, 2026 BUY Strong Buy
+17.6% avg upside
51 analysts
$500.00
71.56% Upside
 ·
CNTA
Centessa Pharmaceuticals
 Jun 24, 2026 HOLD Buy
-22.5% avg upside
19 analysts
 — +0.0%
IRD
Opus Genetics
 Jun 17, 2026 BUY Strong Buy
+160.5% avg upside
24 analysts
$10.00
150.08% Upside
 ·
DSGN
Design Therapeutics
 Jun 15, 2026 BUY Strong Buy
+35.9% avg upside
9 analysts
$21.00
57.21% Upside
 ·
LEGN
Legend Biotech
 Jun 15, 2026 BUY Strong Buy
+134.2% avg upside
27 analysts
$75.00
161.41% Upside
 -15.5%
DTIL
Precision BioSciences
 Jun 09, 2026 BUY Strong Buy
+224.8% avg upside
12 analysts
$20.00
174.29% Upside
 -5.2%
TRDA
Entrada Therapeutics Inc
 Jun 03, 2026 BUY Strong Buy
+179.1% avg upside
10 analysts
$23.00
197.13% Upside
 +3.5%
EVMN
Evommune, Inc.
 May 15, 2026 BUY Strong Buy
+99.8% avg upside
12 analysts
$50.00
98.53% Upside
 +5.6%
PRME
Prime Medicine, Inc.
 May 12, 2026 BUY Strong Buy
+191.2% avg upside
16 analysts
$11.00
220.76% Upside
 -7.3%
SRPT
Sarepta Therapeutics
 May 07, 2026 BUY Buy
+264.2% avg upside
49 analysts
$37.00
119.61% Upside
 -17.0%
TSE:MSCL
Satellos Bioscience
 Apr 20, 2026 BUY Strong Buy
+209.6% avg upside
6 analysts
$56.95
458.33% Upside
 ·
PRQR
ProQR
 Apr 09, 2026 BUY Strong Buy
+652.4% avg upside
18 analysts
$9.00
488.19% Upside
 -26.5%
PEPG
PepGen Inc.
 Mar 31, 2026 BUY Strong Buy
+523.9% avg upside
9 analysts
$15.00
782.39% Upside
 -12.4%
KRRO
Korro Bio
 Mar 13, 2026 BUY Strong Buy
+118.2% avg upside
19 analysts
$22.00
73.23% Upside
 -13.7%
BMRN
BioMarin Pharmaceutical
 Sep 25, 2025 HOLD Strong Buy
+60.3% avg upside
52 analysts
 — +6.2%
MGX
Metagenomi, Inc.
 Sep 25, 2025 HOLD Strong Buy
+698.2% avg upside
7 analysts
 — -45.6%
FDMT
4D Molecular Therapeutics
 Sep 25, 2025 HOLD Strong Buy
+206.3% avg upside
15 analysts
 — +8.7%
SLN
Silence Therapeutics
 Sep 25, 2025 HOLD Strong Buy
+222.6% avg upside
10 analysts
 — +22.0%
DYN
Dyne Therapeutics
 Sep 25, 2025 HOLD Strong Buy
+82.7% avg upside
30 analysts
 — +61.6%
JSPR
Jasper Therapeutics
 Sep 25, 2025 HOLD Strong Buy
+8195.7% avg upside
17 analysts
 — -79.8%
BEAM
Beam Therapeutics
 Sep 25, 2025 HOLD Strong Buy
+47.3% avg upside
25 analysts
 — +47.9%
BBIO
BridgeBio Pharma
 Sep 25, 2025 HOLD Strong Buy
+30.2% avg upside
34 analysts
 — +42.8%
NTLA
Intellia Therapeutics
 Sep 25, 2025 HOLD Buy
+136.8% avg upside
37 analysts
 — -27.1%
RCKT
Rocket Pharmaceuticals
 Sep 25, 2025 HOLD Buy
+405.3% avg upside
29 analysts
 — -7.2%
IONS
Ionis Pharmaceuticals
 Sep 25, 2025 HOLD Strong Buy
+4.1% avg upside
43 analysts
 — +25.2%
CRSP
Crispr Therapeutics AG
 Sep 23, 2025 BUY Buy
+36.7% avg upside
41 analysts
$75.00
36.62% Upside
 -9.6%
LENZ
LENZ Therapeutics
 Jan 29, 2024 HOLD Buy
+308.6% avg upside
17 analysts
 — +159.6%
LGND
Ligand Pharma
 Jun 16, 2022 BUY Strong Buy
-25.0% avg upside
15 analysts
$77.00
74.69% Downside
 +64.8%
🔒 23 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Kostas Biliouris — Frequently Asked Questions
How accurate are Kostas Biliouris's stock ratings?
Based on the calls 13Foresight could measure, about 47% of Kostas's ratings were profitable over a one-year hold, with an average return of +8.5% per rating, or +0.4% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Kostas ranked on 13Foresight?
Kostas Biliouris is currently ranked #1614 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Kostas cover?
Kostas most recently has ratings on ALNY, CNTA, IRD, DSGN, LEGN, DTIL, TRDA, EVMN, PRME, SRPT, TSE:MSCL, PRQR and 16 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.